Quick Overview
- Street consensus projects first-quarter earnings per share of $6.05 with sales reaching $9.76 billion, representing 3.1% annual growth
- Analyst sentiment leans toward Buy with average target price of $736.24, suggesting approximately 11% potential gain from current ~$665 level
- Primary focus: profitability improvement, with divisional margins projected to climb toward 11%
- Latest awards feature $475 million Glide Phase Interceptor contract adjustment and successful YFQ-48A Talon Blue drone initial engine test
- Shares have declined 2% during the last 30 days, lagging the aerospace/defense industry’s 10.3% advance
Northrop Grumman unveils its first-quarter 2026 financial performance Tuesday morning before markets open. Following an extended period of substantial development investments, the critical question for shareholders centers on one issue: has profitability expansion finally materialized?
Northrop Grumman Corporation, NOC
Street analysts anticipate earnings of $6.05 per share alongside $9.76 billion in quarterly sales. These figures represent a sequential decline from the fourth quarter’s $7.23 earnings per share and $11.7 billion revenue performance, though this pattern aligns with industry norms. Defense industry participants historically deliver peak results during the year’s final quarter.
Compared to the prior-year period, revenue projections indicate 3.1% expansion. This would mark a significant turnaround from the 6.6% contraction NOC experienced during last year’s opening quarter.
During the previous reporting period, Northrop exceeded expectations on both top-line and operating profit metrics. Quarterly revenue totaled $11.71 billion, climbing 9.6% annually. Per-share earnings reached $7.23, surpassing the $6.99 Street estimate. The single disappointment emerged from full-year earnings guidance, which fell short of analyst projections.
Shares currently trade in the $665–$667 range, positioned near the midpoint of the 52-week spectrum spanning $450.13 to $774.00. Wall Street price objectives have been trending upward. Wells Fargo launched coverage with a Buy recommendation and $800 target on March 31. Deutsche Bank elevated its price goal to $778 on April 8. Jefferies adjusted its Hold-rated objective upward to $710 on April 9.
Earnings estimates have improved 0.51% across the preceding 60 days. Revenue projections gained 0.24%. While incremental, the trajectory remains constructive.
Profitability Expansion Under Scrutiny
The paramount issue entering Tuesday’s announcement centers on whether margin enhancement is manifesting in actual financial results. Analysts project divisional profitability margins recovering to approximately 11%.
The Aeronautics division is cycling past a B-21 Raider development expense from the comparable year-ago quarter, which should provide tailwinds. Mission Systems stands to gain from improved program composition. Should both units perform as anticipated, it would indicate that Northrop’s capital-intensive development period is genuinely reaching an inflection point.
Full-year earnings guidance also commands attention. Current guidance spans $27.40 to $27.90 per share. Analysts expect leadership to maintain that outlook, though some believe the more compelling upside narrative unfolds during 2027.
Recent Program Awards Set the Context
Northrop has experienced an active April regarding contract announcements. The defense contractor secured a $475 million modification to expedite its Glide Phase Interceptor initiative. Its YFQ-48A Talon Blue autonomous combat platform successfully completed initial engine operations on April 17. Additionally, the Sentinel intercontinental ballistic missile program continues progressing toward an inaugural flight scheduled for 2027.
NOC has retreated approximately 2% throughout the past month. The broader aerospace and defense industry has advanced 10.3% during the identical timeframe, positioning Northrop among the segment’s relative underperformers heading into the earnings release.
Industry competitors have already begun their reporting cycle. AAR delivered 24.6% revenue expansion and exceeded forecasts, with shares surging 9.9%. Byrna achieved 10.9% growth but disappointed expectations, tumbling 38.3%.
Analysts have maintained relatively stable estimates throughout the last 30 days, implying limited anticipation of significant deviations in either direction.
